Latest News and Press Releases

NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...

Clinically and statistically significant efficacy in the triple negative breast cancer cohort with a p-value of 0.013 and a 75.2% reduction in risk of relapse or death in favor of investigational...

Data Safety Monitoring Board met on October 15, 2018 for final analysis Interim and final results of the Phase 2b study to be presented on Monday, October 22, 2018 during an oral presentation at the...

Interim and Updated Final Clinical Data to be Presented Conference Call on October 22, 2018 at 8:00 a.m. ET NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc....

NEW YORK, Oct. 02, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...

NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...

NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...

NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...

Oral Presentation of NeuVax + Herceptin in the Adjuvant Treatment of Triple-Negative Breast Cancer Conference Scheduled for October 19-23, 2018 in Munich, Germany NEW YORK, July 23, 2018 (GLOBE...

NEW YORK, July 20, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel...